JUN 0 5 2006

Atty. Dkt. No. 072121-0307 (19099.004)

HETHE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Paul A. Barsanti, et al.

Title:

BENZIMIDAZOLE

QUINOLINONES AND USES

THEREOF

Appl. No.:

10/644,055

Filing Date:

August 19, 2003

Art Unit:

1614

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.

Joseph P. Meara

(Printed Name)

(Signature)

June 1, 2006

(Date of Deposit)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed non-U.S. patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

06/06/2006 MAHMED1 00000092 502350 10644055

01 FC:1806

180.00 DA

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR § 1.97(b)(3), before the mailing date of the first Office Action on the merits. In the event that an Office Action on the merits has been mailed to applicants, then the listed documents are being submitted in compliance with 37 CFR § 1.97(c)(2), and the Commissioner is hereby authorized to charge the fee of \$180.00 (Fee Code 1806) set forth in 37 CFR § 1.97(c)(2) and § 1.17(p) to Deposit Account No. 50-2350 for such purpose. The fee is not to be charged to the Deposit Account unless an Office Action on the merits has been mailed to Applicants.

RELEVANCE OF EACH DOCUMENT

The documents listed on the attached PTO/SB/08 were cited as being relevant during the prosecution of related European and U.S. applications. Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-2350. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-2350.

Respectfully submitted,

Date June 1, 2006

FOLEY & LARDNER LLP

Customer Number: 23524

Telephone: (60)

(608) 258-4303

Facsimile:

(608) 258-4258

Joseph P. Meara

Attorney for Applicants

Registration No. 44,932

MODIFIED PTO/SB/08 (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for for	rm 1449B/	PTO/	QLE)	Complete if Known		
	INFORMATION	DISCLO	SUŔE		Application Number	10/644,055	
	STATEMENT B	Y APPLI	CANT	JUN 0 5 2008	Filing Date	8/19/2003	
	Date Submitted	· luna 1	2006	1014 o a vouc	First Named Inventor	Paul A. Barsanti, et al.	
			\B		Group Art Unit	1614	
	(use as many shee	ets as ne	cessat	W. at	Examiner Name		
Sheet	1	of	1	TRADE	Attorney Docket Number	072121-0307 (19099.004)	

				U.S. PATENT DOCUMENTS		
Examiner Initials*		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant
	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
		WO 01/28993	Merck & Co., Inc.	4/26/2001			
		WO 02/18383	Chiron Corporation	3/7/2002			
		WO 00/20400	Axys Pharmaceuticals, Inc.	4/13/2000			
		EP 0290153	Pfizer Limited	11/9/1988		1	

	_	NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s publisher, city and/or country where published.			
		European Search Report dated February 28, 2006 for EP 05017665.0.			
		Ukrainets, et al., "Effective Synthesis of 3-(Benzimidazol-2-yl)-4-Hydroxy-2-Oxo-1,2-Dihydroquinolines," Tetrahedron Letters, Vol. 36, No. 42, 1995, pp. 7747-7748.			
		Carla Heise, et al., "In vivo Preclinical Evaluation of Tyrosine Kinase Inhibitors with Potent Effects on Tumor Angiogenesis, Growth and Metastasis," Abstract and presentation material for a presentation at the American Association for Cancer Research meeting held in April, 2002.			

Examiner Signature	Date Considered
45V4441155	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.